Nagoba BS, Rayate AS. Hepatitis E virus infections. World J Virol 2024; 13(2): 90951 [PMID: 38984082 DOI: 10.5501/wjv.v13.i2.90951]
Corresponding Author of This Article
Basavraj S Nagoba, PhD, Assistant Dean, Professor, Department of Microbiology, Maharashtra Institute of Medical Sciences & Research (Medical College), Vishwanathpuram, Ambajogai Road, Latur 413531, India. dr_bsnagoba@yahoo.com
Research Domain of This Article
Virology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Virol. Jun 25, 2024; 13(2): 90951 Published online Jun 25, 2024. doi: 10.5501/wjv.v13.i2.90951
Hepatitis E virus infections
Basavraj S Nagoba, Abhijit S Rayate
Basavraj S Nagoba, Department of Microbiology, Maharashtra Institute of Medical Sciences & Research (Medical College), Latur 413531, India
Abhijit S Rayate, Department of Surgery, Maharashtra Institute of Medical Sciences & Research (Medical College), Latur 413531, India
Author contributions: Nagoba B and Rayate A contributed to the idea behind the manuscript, literature search, collection, writing the paper, modification of content and final approval of the draft.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Basavraj S Nagoba, PhD, Assistant Dean, Professor, Department of Microbiology, Maharashtra Institute of Medical Sciences & Research (Medical College), Vishwanathpuram, Ambajogai Road, Latur 413531, India. dr_bsnagoba@yahoo.com
Received: December 18, 2023 Revised: March 2, 2024 Accepted: April 7, 2024 Published online: June 25, 2024 Processing time: 188 Days and 23.7 Hours
Abstract
Hepatitis E virus (HEV) infection is now endemic worldwide. Most patients with acute infection recover uneventfully. Outbreaks and sporadic cases, particularly in high-risk individuals are emerging increasingly. The patients with risk factors like pregnancy and pre-existing chronic liver disease, present with or progress rapidly to severe disease. Immuno-suppression in post-transplant patients is an additional risk factor. Standardized FDA-approved diagnostic tests are the need of the hour. Further studies are needed to establish guideline-based treatment regimen and outbreak preparedness for HEV to decrease global morbidity, mortality, and healthcare burden. Policies for screening donors and transplant cases are required.
Core Tip: In this editorial we have tried to throw light on various aspects of hepatitis E virus, that help in better understanding about the virus, disease process, various diagnostic approaches, treatment and prevention. We are sure that this will be helpful to plan proper surveillance and management protocols with improved outcomes.
